Clinical Trials Browser

Pancreatic Neoplasms

NCT02484391 2024-09-19

CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma

Phase 1 Completed

48 enrolled 13 charts

Other hematologic neoplasmSarcoma

Leukemia, Myeloid, Acute, Sarcoma, Myeloid

NCT02168140 2024-02-13

CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma

Phase 1 Completed

16 enrolled

DermatologicLymphoidOther hematologic neoplasm

Hodgkin Disease, Immunoblastic Lymphadenopathy, Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell

NCT02232152 2023-08-07

CPI-613 and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery

Phase 1 Completed

19 enrolled

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

NCT01835041 2023-07-12

CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer

Phase 1 Completed

21 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT04593758 2023-05-24

To Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy of CPI-613® (Devimistat) Plus Hydroxychloroquine in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue

Phase 1/2 Completed

16 enrolled

Sarcoma

Sarcoma, Clear Cell

NCT03504423 2023-01-03

Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas

Phase 3 Completed

528 enrolled 11 charts

Gastrointestinal

Pancreatic Cancer Metastatic

NCT01766219 2019-05-15

CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery

Phase 1/2 Completed

17 enrolled 15 charts

Gastrointestinal

Bile Duct Neoplasms, Carcinoma, Hepatocellular

NCT01839981 2018-12-27

CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Phase 1 Completed

10 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT01768897 2018-07-03

CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1 Completed

67 enrolled

Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Myeloid, Acute

NCT01931787 2018-07-03

CPI-613 in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

Phase 1 Completed

15 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT01034475 2018-07-02

Study to Evaluate Safety, Tolerability, Maximum Tolerated Dose (MTD), Efficacy, and Pharmacokinetics (PKs) of CPI-613 Given Twice Weekly for Three Consecutive Weeks in Patients With Advanced Hematologic Malignancies

Phase 1 Completed

26 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Multiple Myeloma, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00741403 2016-12-29

A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies

Phase 1 Completed

39 enrolled

Lymphoid

Lymphoma, Neoplasm Metastasis, Neoplasms, Recurrence

Clinical Trials

CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer

CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma

CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma

CPI-613 and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery

CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer

To Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy of CPI-613® (Devimistat) Plus Hydroxychloroquine in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue

Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas

CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery

CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

CPI-613 in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

Study to Evaluate Safety, Tolerability, Maximum Tolerated Dose (MTD), Efficacy, and Pharmacokinetics (PKs) of CPI-613 Given Twice Weekly for Three Consecutive Weeks in Patients With Advanced Hematologic Malignancies

A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies